This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

A Study Of Atorvastatin For The Treatment Of High Cholesterol In Patients At High Risk Of Coronary Heart Disease (CHD)

This study has been completed.
Sponsor:
Information provided by:
Pfizer
ClinicalTrials.gov Identifier:
NCT00644709
First received: March 25, 2008
Last updated: March 27, 2008
Last verified: March 2008
  Purpose
A study of the long-term (1 year) effectiveness of atorvastatin to keep patients of high cardiovascular risk at the LDL cholesterol goal of <115 mg/dL

Condition Intervention Phase
Dyslipidemias Drug: Atorvastatin Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicenter, Open-Label Extension Study Of High-Risk Hyperlipidemic Patients Treated With An Atorvastatin Starting Dose Adapted To Their Baseline LDL-C Level

Resource links provided by NLM:


Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Achievement of low-density lipoprotein cholesterol (LDL-C) target of <115 mg/dL [ Time Frame: Week 52 ]

Secondary Outcome Measures:
  • Achievement of LDL-C target and total cholesterol target (<190 mg/dL) concomitantly [ Time Frame: Week 52 ]
  • LDL-C, high-density lipoprotein cholesterol (HDL-C), total cholesterol, and triglyceride levels [ Time Frame: Baseline and Week 6 for base study; Baseline and Weeks 17, 34, and 52 for extension study ]
  • Percent change from baseline of base study in LDL-C, HDL-C, non-HDL-C (triglycerides of >200 mg/dL), total cholesterol, and triglycerides in patients who were statin-naive at baseline of base study [ Time Frame: Baseline and Weeks 17, 34, and 52 ]
  • Achievement of LDL-C target grouped according to whether patients had achieved target at the start of this extension study [ Time Frame: Week 52 ]
  • Adverse events and laboratory test changes [ Time Frame: Weeks 17, 34, and 52 ]
  • Achievement of LDL-C target [ Time Frame: Weeks 17 and 34 ]
  • Achievement of LDL-C target by diabetic patients [ Time Frame: Week 52 ]

Enrollment: 196
Study Start Date: September 2003
Study Completion Date: March 2005
Arms Assigned Interventions
Experimental: Arm A Drug: Atorvastatin
Atorvastatin tablets at starting doses of 10, 20, 40, or 80 mg once daily. Three dose adjustments were allowed at baseline, Week 17, and Week 34. Patients who did not meet the LDL-C target at any of these time points had their doses doubled except for those who were on the 80 mg dose. Treatment was given for 52 weeks.

  Eligibility

Ages Eligible for Study:   30 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Completion of base study
  • Dyslipidemia and at high risk of CHD

Exclusion Criteria:

  • Impaired liver function
  • Gastrointestinal disease that could limit drug absorption
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00644709

Locations
Belgium
Pfizer Investigational Site
Antwerpen, Belgium, 2018
Pfizer Investigational Site
Brasschaat, Belgium, 2930
Pfizer Investigational Site
Brussels, Belgium, 1180
Pfizer Investigational Site
Genk, Belgium, B-3600
Pfizer Investigational Site
Gent, Belgium, 9000
Pfizer Investigational Site
Gilly (charleroi), Belgium, 6060
Pfizer Investigational Site
La Louvière, Belgium, 7100
Pfizer Investigational Site
Mechelen, Belgium, 2800
Pfizer Investigational Site
Menen, Belgium, 8930
Pfizer Investigational Site
Merksem, Belgium, 2170
Pfizer Investigational Site
Mortsel, Belgium, 2640
Pfizer Investigational Site
Roeselare, Belgium, 8800
Pfizer Investigational Site
Seraing, Belgium, 4100
Pfizer Investigational Site
Wilrijk, Belgium, 2610
Pfizer Investigational Site
Wingene, Belgium, 8750
Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
Responsible Party: Director, Clinical Trial Disclosure Group, Pfizer, Inc.
ClinicalTrials.gov Identifier: NCT00644709     History of Changes
Other Study ID Numbers: A2581112
Study First Received: March 25, 2008
Last Updated: March 27, 2008

Additional relevant MeSH terms:
Dyslipidemias
Lipid Metabolism Disorders
Metabolic Diseases
Atorvastatin Calcium
Anticholesteremic Agents
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors

ClinicalTrials.gov processed this record on August 18, 2017